Life Sciences Liquid Biopsy Testing Platforms sector
Strategic acquirers, private equity (buyout funds and growth funds) firms, and valuation benchmarks for Life Sciences Liquid Biopsy Testing Platforms
1.1 - About Life Sciences Liquid Biopsy Testing Platforms sector
Companies in the Life Sciences Liquid Biopsy Testing Platforms category develop and operate non-invasive oncology diagnostics that analyze blood or other biofluids to detect, characterize, and monitor cancer. They integrate validated assays, high-throughput sequencing, and bioinformatics pipelines to deliver actionable genomic insights, enabling earlier detection, therapy selection, and minimal residual disease tracking. Customers rely on these platforms for scalable testing capacity, standardized workflows, and regulatory-grade reporting.
Strategic buyers in liquid biopsy testing typically offer NGS-based circulating tumor DNA panels that profile somatic variants, ddPCR assays for sensitive mutation detection, and MRD monitoring tests integrated with longitudinal data tracking. Vendors provide cfDNA extraction and sample-prep kits optimized for low-input plasma, CTC enrichment systems to capture rare cells, and bioinformatics pipelines for variant calling, methylation analysis, and tumor mutational burden. Many support clinical reporting portals, LIMS integration, and companion diagnostic development within CLIA/CAP-accredited labs.
Primary customers include biopharma clinical development teams, oncology clinics and health systems, and diagnostic laboratories. These companies enable earlier cancer detection, patient stratification for trials and targeted therapies, real-time treatment response monitoring, and cost-efficient alternatives to tissue biopsies. Outcomes include faster study enrollment, improved precision oncology decision-making, higher test throughput, and standardized, audit-ready reporting suitable for regulatory submissions and payer review.
2. Buyers in the Life Sciences Liquid Biopsy Testing Platforms sector
2.1 Top strategic acquirers of Life Sciences Liquid Biopsy Testing Platforms companies
Guardant Health
- Description: Provider of precision oncology solutions that leverage advanced blood and tissue tests, real-world data and AI analytics to deliver insights into disease biology, enable early cancer detection, guide therapy selection and expand access to screening, helping patients enjoy more time free from cancer.
- Key Products:
- Guardant360 Liquid: Blood-based liquid biopsy analyzing cell-free DNA to provide genomic and epigenomic insights, identify actionable alterations and monitor tumor evolution in advanced solid tumors
- Guardant360 CDx: FDA-approved liquid biopsy delivering comprehensive genomic profiling results in under seven days with guideline-recommended actionable biomarkers for treatment selection in advanced solid tumors
- Guardant360 Tissue: Multiomic tissue test offering genomic, transcriptomic and epigenomic data while needing 92% less tissue surface and 40% fewer slides than standard NGS assays
- Guardant Reveal: Tissue-free blood test that detects circulating tumor DNA to assess minimal residual disease and monitor recurrence in early-stage colorectal, breast and lung cancer patients.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
2.2 - Strategic buyer groups for Life Sciences Liquid Biopsy Testing Platforms sector
M&A buyer group 1: Clinical Genomics
OPKO Health
- Type: N/A
- Employees: ●●●●●
- Description: Provider of next-generation healthcare solutions, OPKO Health develops and markets therapies for serious diseases worldwide, leveraging global operating businesses and partnerships to create novel multispecific medicines for cancer and infectious diseases.
- Key Products:
- Marketed Therapies: Portfolio of approved treatments distributed worldwide through commercial partnerships, providing patients with established therapeutic options for serious diseases across multiple global markets
- Multispecific Cancer Medicines (in development): Novel multispecific drug candidates designed to target multiple cancer pathways simultaneously, aiming to improve efficacy and patient outcomes in oncology
- Multispecific Infectious Disease Medicines (in development): Next-generation therapeutics engineered to act on multiple targets within pathogens, pursuing enhanced effectiveness against complex infectious diseases
- Global Operating Businesses: Integrated healthcare operations in the U.S.
- Mexico
- Chile
- Spain
- Ireland and Israel that generate stable profits and support R&D, including manufacturing, distribution and commercialization capabilities for OPKO’s therapies.
Buyer group 2: ████████ ████████
●● companiesBuyer group 3: ████████ ████████
●● companies3. Investors and private equity firms in Life Sciences Liquid Biopsy Testing Platforms sector
3.1 - Buyout funds in the Life Sciences Liquid Biopsy Testing Platforms sector
2.2 - Strategic buyer groups for Life Sciences Liquid Biopsy Testing Platforms sector
4 - Top valuation comps for Life Sciences Liquid Biopsy Testing Platforms companies
4.2 - Public trading comparable groups for Life Sciences Liquid Biopsy Testing Platforms sector
Valuation benchmark group 1: Molecular Diagnostics and Genomics Tools Companies
Agilent Technologies
- Enterprise value: $●●●m
- Market Cap: $●●●m
- EV/Revenue: ●.●x
- EV/EBITDA: ●●.●x
- Description: Provider of design, manufacturing, and marketing of measurement instruments primarily for communications, electronics, life sciences, and chemistry sectors.
- Key Products:
- Gas Chromatographs: Instruments for separating chemical compounds into individual components for analysis
- Liquid Chromatographs: Tools for separating, identifying, and quantifying components in a liquid sample
- Mass Spectrometers: Analyzers for identifying chemical structures and determining molecule weights
- Lab Automation Systems: Robots and software for enhancing efficiency in laboratory workflows
- Genomics Solutions: Products for gene sequencing, expression analysis, and mutation detection.